CFTR and cystic fibrosis: The association between rs7512462 genotype and response to existing pharmaceuticals indicate the potential to refine personalized combinations of modulators, and there is also support that SLC26A9 agonists may yield benefit to any existing pharmacological or gene correction paradigm in CF, independent of CFTR genotype.